BioSpace News Archive

Polyphor announced today that new survival data from clinical and preclinical trials of balixafortide will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany, October 19-23.

Shareholders’ Approval and Launch of Oxurion NV as new Company Name

Voice solution provider now working with academic medical center to explore opportunities to improve patient care

Data presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancer

Adaptimmune Therapeutics plc presented initial data from the first two cohorts of its ongoing studies with its MAGE-A10 and MAGE-A4 SPEAR T-cells in two poster presentations earlier today at the European Society for Medical Oncology (ESMO) Congress in Munich, Germany.

Xofluza (baloxavir marboxil) was approved for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older. The new medication has a novel mechanism of action that, Roche said, inhibits polymerase acidic endonuclease, an enzyme that is essential for the flu virus to replicate.

Regeneron Pharmaceuticals’ Eylea (aflibercept) showed strongly positive data in a Phase III trial in patients with moderately severe and severe non-proliferative diabetic retinopathy (NPDR). The trial met its 52-week primary endpoint and key secondary endpoints.

TESARO, Inc. will announce third-quarter 2018 financial results on Thursday, November 1, 2018, after the close of the U.S. financial markets.

Saving oncology researchers valuable time, whilst maximising the understanding of their dataset

Lupin Neurosciences today announces that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending the marketing authorization of NaMuscla™ (mexiletine hydrochloride) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders.